Potassium, Inward Rectifier Channels
Cambridge Bioscience, through our collaboration with ChanTest, offers access to screening services to the following inward rectifier potassium channel targets:
Gene Name: KCNA1
Validated Assay/Platform: IonWorks Quattro™, PatchXpress® &QPatch HT
Description: The human KCNA1 gene encodes the pore-forming subunit of Kir1.1, a voltage-gated potassium channel. Mutations in KCNA1 cause several congenital disorders including episodic ataxia type 1, neuromyotonia, and autosomal dominant hypomagnesia. Kir1.1 channels expressed in neurons are therapeutic targets in multiple sclerosis, stroke and seizure.
Gene Name: KCNJ2
Validated Assay/Platform: IonWorks Quattro™ & QPatch HT
Description: The human KCNJ2 gene encodes the pore-forming subunit of Kir2.1, an inwardly rectifying potassium channel. Mutations in KCNJ2 have been linked to inherited cardiac diseases including Andersens syndrome (a form of long QT with neurologic involvement), Short QT syndrome, and familial atrial fibrillation. Kir2.1 channels expressed in heart are anti-targets in cardiac risk assessment.
Gene Name: KCNJ3/KCNJ5
Validated Assay/Platform: PatchXpress®
Description: The human KCNJ3 and KCNJ5 genes encode the pore-forming subunits of heteromeric Kir3.1/Kir3.4, an inward rectifier potassium channel. Kir3.1/Kir3.4 channels expressed in heart are linked to M2 muscarinic acetylcholine receptors that mediate vagal inhibitory control of heart rate. Kir3.1/Kir3.4 is a potential target for treatment of atrial fibrillation.
Gene Name: KCNJ11/ABCC8
Validated Assay/Platform: Manual Patch Clamp
Description: Kir6.2/SUR1 is an inwardly-rectifying, ATP-sensitive, K+-selective channel expressed in the pancreas, neuroendocrine cells, and the central nervous system. Kir6.2/SUR1 channels are therapeutic targets in diabetes, obesity, and Parkinson's disease.
Gene Name: KCNJ11/ABCC9
Validated Assay/Platform: PatchXpress® & QPatch HT
Description: The human KCNJ11 gene encodes the pore-forming subunit of heteromeric Kir6.2/SUR2A, an ATP-sensitive, inwardly rectifyiing potassium channel. ABCC9 encodes the SUR2A subunit which confers sulfonylurea sensitivity. Kir6.2/SUR2A channels expressed in heart are therapeutic targets for cardiac ischemia.
Cambridge Bioscience, through our collaboration with ChanTest, offers access to the widest range of screening platforms, from manual patch clamp up to the most recent innovations in automated electrophysiology, allowing you to select the right balance of speed, throughput and data quality to suit your needs.
To find out more about each of these platforms, please Click Here
Request A No Obligation Quote
To discuss an ion channel screening project, please contact our experienced team by Clicking Here